We are live on ! Find out more
NERV icon

Minerva Neurosciences
NERV

67 hedge funds and large institutions have $177M invested in Minerva Neurosciences in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 19 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 19

4% more capital invested

Capital invested by funds: $170M → $177M (+$6.5M)

0.03% more ownership

Funds ownership: 9.08% → 9.11% (+0.03%)

0% more funds holding

Funds holding: 67 → 67 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

Holders
67
Holders Change
–
Holders Change %
0%
% of All Funds
1.54%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
8
Increased
23
Reduced
19
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$4.19M
2
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$1.28M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$552K
4
HCMT
Highland Capital Management (Texas)
Texas
+$519K
5
AG
Artal Group
Luxembourg
+$292K

Top Sellers

Rank Fund Capital Flow
1
AC
Ascend Capital
California
-$4.96M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$669K
3
JP Morgan Chase
JP Morgan Chase
New York
-$348K
4
BlackRock
BlackRock
New York
-$339K
5
Deutsche Bank
Deutsche Bank
Germany
-$165K
Name Holding Trade Value Shares
Change 		Change in
Stake
Federated Hermes
1
Federated Hermes
Pennsylvania
$47.1M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$28.6M -$669K -13,919 -2%
HCMT
3
Highland Capital Management (Texas)
Texas
$14M +$519K +10,792 +4%
BlackRock
4
BlackRock
New York
$12.3M -$339K -7,060 -3%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$10.4M +$11.1K +231 +0.1%
Vanguard Group
6
Vanguard Group
Pennsylvania
$8.78M +$552K +11,482 +7%
Franklin Resources
7
Franklin Resources
California
$7.72M – – –
IVAV
8
Index Venture Associates V
Jersey
$5.7M – – –
Millennium Management
9
Millennium Management
New York
$5.59M +$4.19M +87,152 +354%
SFM
10
Sphera Funds Management
Israel
$4.84M – – –
CAM
11
Cormorant Asset Management
Massachusetts
$3.8M – – –
JP Morgan Chase
12
JP Morgan Chase
New York
$3.75M -$348K -7,236 -9%
MWNA
13
Marshall Wace North America
New York
$3.11M +$135K +2,801 +5%
State Street
14
State Street
Massachusetts
$2.92M +$243K +5,052 +9%
Northern Trust
15
Northern Trust
Illinois
$1.89M -$162K -3,372 -8%
AG
16
Artal Group
Luxembourg
$1.88M +$292K +6,087 +19%
Dimensional Fund Advisors
17
Dimensional Fund Advisors
Texas
$1.74M +$1.28M +26,698 +329%
Geode Capital Management
18
Geode Capital Management
Massachusetts
$1.7M +$10.9K +226 +0.7%
DCM
19
DAFNA Capital Management
California
$1.07M – – –
TCIM
20
TIAA CREF Investment Management
New York
$962K +$40.4K +841 +5%
BCM
21
Bridgeway Capital Management
Texas
$908K +$25.2K +525 +3%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$652K -$40.2K -836 -6%
Handelsbanken Fonder
23
Handelsbanken Fonder
Sweden
$594K – – –
Alyeska Investment Group
24
Alyeska Investment Group
Illinois
$507K -$4.37K -91 -0.9%
Morgan Stanley
25
Morgan Stanley
New York
$376K +$14.2K +295 +4%
1
2 3

NERV Hedge Fund Activity: Q1 2018 in Review

67 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Minerva Neurosciences (NERV) for Q1 2018, worth a combined $177M — up 3.8% from $170M a quarter earlier.

Fund positioning in NERV was balanced in Q1 2018: 8 funds opened new positions, 8 closed out, 23 added to existing stakes and 19 trimmed.

The largest buyer was Millennium Management, adding an estimated $4.19M. The largest seller was Ascend Capital, exiting entirely with an estimated $4.96M sold.

  • 67 institutional investors held Minerva Neurosciences (NERV) as of Q1 2018, unchanged from Q4 2017.
  • Funds reported $177M of Minerva Neurosciences stock for Q1 2018, up 3.8% quarter-over-quarter.
  • 8 funds opened new Minerva Neurosciences positions in Q1 2018 and 8 closed out, a net change of 0 holders.
  • The largest Minerva Neurosciences buyer in Q1 2018 was Millennium Management, an estimated $4.19M added.
  • The largest Minerva Neurosciences seller in Q1 2018 was Ascend Capital, an estimated $4.96M sold.

Based on aggregated 13F filings for Q1 2018.